Variant · Snv
NFE2L2 E79Q
CI-VAR-00000852Explore in graph →CIViC 3960
Curated evidence
Evidence by cancer (1 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24130096
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Unmapped disease1unmapped disease | ||||||||
| NFE2L2 E79Q | (functional) | Functional | D | Supports Gain Of Function | 1 | submitted | EID10277A fluorescence resonance energy transfer (FRET) assay was used to assess the interaction between the Nrf2 (NFE2L2) ETGE motif and the Keap1 Kelch binding domain. A peptide containing the E79Q mutation… (full text at CIViC) PMID 24130096 · Schaap et al., 2013 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available